MetaVia’s DA-1726 shows weight and liver fat reductions
MetaVia announced that an abstract on DA-1726, a dual oxyntomodulin analogue targeting GLP-1 and glucagon receptors, has been accepted for a poster presentation at ObesityWeek 2026 in Washington, DC. The poster, titled “DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile
<p>MetaVia announced that an abstract on DA-1726, a dual oxyntomodulin analogue targeting GLP-1 and glucagon receptors, has been accepted for a poster presentation at ObesityWeek 2026 in Washington, DC. The poster, titled “DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile</p>